Latest KFF Health News Stories
Cholesterol Drug Prevents Heart Attacks — But It Doesn’t Come Cheap
A cholesterol-lowering drug called Repatha cuts the risk of heart attacks, strokes and heart-related death by 20 percent, according to a new study.
$89,000 Orphan Drug Gets A New Owner — And Likely A New Price
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
Sticker Shock Forces Thousands Of Cancer Patients To Skip Drugs, Skimp On Treatment
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
By The Numbers: Trump’s Choice For FDA Chief Is Versatile, Entrenched In Pharma
The numbers show that President Trump’s choice for FDA commissioner, Scott Gottlieb, has long-standing ties to pharmaceutical companies as a board member or consultant and that he had to recuse himself multiple times while working at the FDA.
HMO Doctors Take Pains To Slash Opioid Prescriptions
A Kaiser Permanente pain management program in Southern California aims to help patients taper off addictive painkillers. Some doctors and patients see it as a godsend; others complain that patients have been cut off medications they need.
Trump, Dems Look For Common Ground On Drug Prices
Two Democratic congressmen met with President Trump to seek his support for a bill to expand the government’s ability to negotiate drug prices, but it’s not clear it would have much impact or will gain support.
Dentists Work To Ease Patients’ Pain With Fewer Opioids
Dentistry is at a crossroads and many in the field are reassessing their narcotics prescribing habits.
Three Key Senators Ask GAO To Investigate Possible Abuses Of The Orphan Drug Act
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
‘Right-To-Try’ Laws Expose Dying Patients To Exploitation, Ethicists Warn
More than 30 states have laws on the books to allow dying patients the right to try experimental treatments. But these treatments may not be covered by insurance, and ethicists worry vulnerable people could be exploited near the end of their lives. The laws may also duplicate a process the FDA already has in place.
Making Multiple Drugs In One Factory Risks Scary Side Effect Of Shortages
Hundreds of drug brands are being made in giant contract facilities. When a plant shuts down, a widespread drain on supply can result.
Patient Advocacy Groups Rake In Donations From Pharma
A new study shows that 83 percent of the largest patient advocacy groups take contributions from drug, medical device or biotech firms.
Instead Of Trashing A $600 EpiPen, Some Patients Get A Refill
Epinephrine, the active ingredient in EpiPens, expires after 18 months, and the auto-injector device can’t be refilled or reused. Health professionals are looking for work-arounds they say could save the health system millions.
President Trump And I Take The Same Drugs — Except One
An aging writer discovers there are worse things than going bald after examining the side effects of a popular hair loss drug purportedly used by President Donald Trump.
Docs In Northwest Tweak Aid-In-Dying Drugs To Prevent Prolonged Deaths
Some terminal patients, typically high-dose opioid users, who choose to end their lives have taken many hours, even days, to die.
5 Reasons Why An $89,000 Drug Has Congress Fuming
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
How Long You Stay On Opioids May Depend On The Doctor You See In the ER
A study shows some emergency physicians wrote far more opioid prescriptions and Medicare patients who saw those doctors were more likely to still be taking the addictive painkillers months later.
Former FDA Chief Cites 5 Things To Watch On Drug Approvals And Keeping Drugs Safe
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
Drugmaker Marathon ‘Pausing’ Delivery Of $89,000-A-Year Muscular Dystrophy Drug
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Grassley Launches Inquiry Into Orphan Drugs After KHN Investigation
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
Dozens Of New Cancer Drugs Do Little To Improve Survival, Frustrating Patients
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
